Exp Clin Endocrinol Diabetes 2010; 118(3): 158-160
DOI: 10.1055/s-0029-1215586
Article

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Human Multidrug Resistance-1 Gene Expression Levels in Graves-Basedow Disease

Ş. Çetinkalp1 , M. Karadeniz1 , M. Erdoğan1 , Z. Eroğlu2 , A. Zengi1 , B. Kosova2 , C. Yilmaz1 , B. Tezcanli2 , T. Kabalak1 , A. G. Özgen1
  • 1Department of Endocrinology and Metabolism, Ege University Medical School, Izmir, Turkey
  • 2Department of Medical Biology, Ege University Medical School, Izmir, Turkey
Further Information

Publication History

received 20.11.2007 first decision 24.10.2008

accepted 11.03.2009

Publication Date:
09 February 2010 (online)

Abstract

Object: Multidrug resistance 1 gene is responsible for the resistance of a large variety of drugs in human cells. We tried to evaluate this in the present study in thyroid stimulant hormone receptor antibody positive subjects.

Method: In study enrolled 23 female and 10 male subjects. Hyperthyroid subjects were treated with PTU and remission was assured between 6-12 months. Blood samples were collected before the start of this treatment. Permission for this study was taken from the patients and the local ethical committee.

Results: Serum F-T3, F-T4 levels in Graves subjects were markedly high, whereas TSH levels were markedly low than normal range. We also found that with increased age of the Graves’ subjects, MDR-1 gene expression decreased. There was also a direct correlation between blood MDR-1 gene expression and TSH-R Ab levels in patients with Graves's disease. We observed that the duration of being euthyroid was lengthened with the elevation of MDR-1 gene expression. There was a direct correlation between blood MDR-1 gene expression levels and ultrasonografic size of thyroid gland.

Conclusion: As a result, raised blood MDR-1 gene expression levels in patients with Graves-Basedow disease may be associated with the activity of the disease and the resistance to its treatment. The more blood MDR-1 expression increases the more the duration of being euthyroid increases.

References

  • 1 Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance.  Annu Rev Biochem. 1989;  58 137-171
  • 2 Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by multidrug transporter.  Annu Rev Biochem. 1993;  62 385-427
  • 3 Higgins CF. ABC transporters: from microorganisms to mas.  Annu Rev Cell Biol. 1992;  8 67-113
  • 4 Higgins CF. The ABC of channel regulation.  Cell. 1995;  82 693-696
  • 5 Cordon-Cardo C, O'Brien JP, Casals D. et al . Multidrug resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites.  Proc Natl Acad Sci USA. 1989;  86 695-698
  • 6 Thiebaut F, Tsuruo T, Hamada H. et al . Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.  Proc Natl Acad Sci USA. 1987;  84 7735-7738
  • 7 Cordon Cardo C, O’Brien JP, Boccia J. et al . Expression of the multidrug resistance gene product (P-glycoprotein) in normal human and tumor tissues.  J Histochem Cytochem. 1990;  38 1277-1287
  • 8 Fojo AT, Ueda K, Slamon DJ. et al . Expression of a multidrug resistance gene in human and tumor tissues.  Proc Natl Acad Sci USA. 1987;  84 265-269
  • 9 Jorgensen C, Sun R, Rossi JF. et al . Expression of a multidrug resistance gene in human rheumatoid synovium.  Reumatol Int. 1995;  15 83-86
  • 10 Maillefert JF, Maynadie M, Tebib JG. et al . Expression of the multidrug resistance glycoprotein 170 in the peripheral blood lymphocytes of rheumatoid arthritis patients. The percentage of lymphocytes expressing glycoprotein 170 is increased in patients treated with prednisolone.  Br J Rheumatol. 1996;  35 430-435
  • 11 Yvonne R-P, Elena S-V, Juan J-O. et al . P-glycoprotein in autoimmune diseases.  Autoimmunity Reviews. 2004;  3 ((3)) 188-192
  • 12 Ruiz-Soto R, Richaud-Patin Y, Lopez-Karpovitch X. et al . Multidrug resistance-1 (MDR-1) in autoimmune disorders III: increased P-glycoprotein activity in lymphocytes from immune thrombocytopenic purpura patients.  Exp Hematol. 2003;  31 483-487
  • 13 Levy AS, Cunningham-Rundles S, Mazza B. et al . High P-glycoprotein-mediated export observed in patients with a history of idiopathic thrombocytopenic purpura.  Br J Haematol. 2002;  118 836-838
  • 14 Diaz-Borjon A, Richaud-Patin Y, Alvarado de la Barrera C. et al . Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. Part II: increased P-glycoprotein activity in lymphocytes from systemic lupus erythematosus patients might affect steroid requirements for disease control.  Joint Bone Spine. 2000;  67 40-48
  • 15 Londei M, Bottazzo GF, Feldmann M. Human T-cell clones from autoimmune thyroid glands: Spesific recognition of autologous thyroid cells.  Science. 1985;  228 85-89
  • 16 Martin A, Goldsmith NK, Friedman EW. et al . Intrathyroidal accumulation of T cell phenotypes in autoimmune thyroid disease.  Autoimmunity. 1990;  6 269-281
  • 17 Martin A, Davies TF. T cells and human autoimmune thyroid disease: Emerging data show lack of need to invoke suppressor T-cell problems.  Thyroid. 1992;  2 247-261
  • 18 Peter NG, Terry FD. New insights into the Thyroid-Stimulating Hormone Receptor: The major antigen of Graves’ Disease.  Endocrinol Metab Clin North A. 2000;  29 ((2)) 267-286
  • 19 Orgiazzi J. Anti-TSH receptor antibodies in clinical practise.  Endocrinol Metab Clin North A. 2000;  29 ((2)) 339-355
  • 20 Cooper DS. Antithyroid drugs fort he treatment of hyperthyroidism caused by Graves’ disease.  Endocrinol Metab Clin North Am. 1998;  27 225-247
  • 21 Hedley AJ, Young RE, Jones SJ. Antithyroid drugs in the treatment of hyperthyroidism of Graves’ disease: Long term follow-up of 434 patient. Scottish Automated Follow-up Register Group.  Clin Endocrinol (Oxf). 1989;  31 209-218
  • 22 Alsanea O, Clark O. Treatment of Graves’ disease: The advantages of surgery.  Endocrinol Metab Clin North A. 2000;  29 ((2)) 321-337
  • 23 Ford JM. Modulators of multidrug resistance. Preclinical studies.  Hematol/Oncol Clin North A. 1995;  9 337-359
  • 24 Truman JP, Garban F, Choqueux C. et al . HLA class II signaling mediates cellular activation and programmed cell death.  Exp Hematol. 1996;  24 1409-1415
  • 25 Distelhorst CW, Dubyak G. Role of calcium in glucocorticosteroid-induced apoptosis of thymocytes and lymphoma cells: resurrection of old theries by new finding.  Blood. 1998;  91 731-734
  • 26 Vilpo J, Koski T, Vilpo L. Calcium antagonists potentiate P-glycoprotein-independent anticancer drugs in chronic lymphocytic leukemia cells in vitro.  Haematologica. 2000;  85 806-813
  • 27 O’Brian CA, Ward NE, Stewart JR. et al . Prospects for targeting protein kinase C isozyme in the therapy of drug resistant cancer-an evolving story.  Cancer Metastasis Rev. 2001;  20 95-100
  • 28 Yudoh K, Matsuno H, Nakazawa F. et al . Increased expression of multidrug resistance of P-glycoprotein on Th1 cells correlates with drug resistance in rheumatoid arthritis.  Arthritis Rheum. 1999;  42 2014-2015

Correspondence

M. KaradenizMD 

Endocrinology and Metabolism Disease

Ege University Hospital

35100 Bornova

Izmir

Turkey

Phone: 90/232/347 30 85

Fax: 90/232/373 77 01

Email: muammerkaradenis@gmail.com

    >